-
1Academic Journal
Authors: EVERSDIJK, Margarita, SANGHELI, Marina, LISNIC, Vitalie, SHIMON, Victoria, BELENCIUC , Anna
Source: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 80 No. 3 (2024): Medical Sciences; 41-45 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 80 Nr. 3 (2024): Ştiinţe medicale; 41-45 ; Вестник Академии Наук Молдовы. Медицина; Том 80 № 3 (2024): Медицина; 41-45 ; 1857-0011
Subject Terms: рассеянный склероз, окрелизумаб, эффективность, качество жизни, модифицирующие течение заболевания терапии, scleroza multiplă, ocrelizumab, eficacitate, calitatea vieții, terapii de modificare a bolii, multiple sclerosis, efficacy, quality of life, disease-modifying therapies
File Description: application/pdf
Relation: https://bulmed.md/bulmed/article/view/3717/3708; https://bulmed.md/bulmed/article/view/3717
-
2Academic Journal
Authors: Eversdijk, M., Sangheli, M.M., Lisnic, V.S., Şimon, V.I., Belenciuc, A.V.
Source: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 80 (3) 41-45
Subject Terms: Calitatea vieţii, eficacitate, модифицирующиетечение заболевания терапии, efficacy, эффективность, multiple sclerosis, рассеянный склероз, окрелизумаб, quality of life, ocrelizumab, scleroza multiplă, terapii de modificare a bolii, disease-modifying therapies, качество жизни
File Description: application/pdf
Access URL: https://ibn.idsi.md/vizualizare_articol/220186
-
3Academic Journal
Authors: Litvinova, O. V., Posilkina, O. V.
Source: Management, economy and quality assurance in pharmacy; № 4 (60) (2019); 55-63
Управление, экономика и обеспечение качества в фармации; № 4 (60) (2019); 55-63
Управління, економіка та забезпечення якості в фармації; № 4 (60) (2019); 55-63Subject Terms: УДК 615.1:616.832-004.21, рассеянный склероз, глатирамера ацетат, финголимод, алемтузумаб, окрелизумаб, multiple sclerosis, glatiramer acetate, fingolimod, alemtuzumab, осrеlіzumаb, UDC 615.1:616.832-004.21, розсіяний склероз, глатирамеру ацетат, фінголімод, окрелізумаб, 3. Good health
File Description: application/pdf
-
4Academic Journal
Authors: E. V. Popova, M. I. Alexandrov, I. A. Trubnikova, S. R. Zeynalova, Е. В. Попова, М. И. Александров, И. А. Трубникова, С. Р. Зейналова
Source: Meditsinskiy sovet = Medical Council; № 10 (2021); 108-111 ; Медицинский Совет; № 10 (2021); 108-111 ; 2658-5790 ; 2079-701X
Subject Terms: окрелизумаб, COVID-19, pandemic, cytokine storm, ocrelizumab, пандемия, цитокиновый шторм
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6271/5685; Zhou F., Yu T., Du R., Fan G., Liu Y, Liu Z. et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/s0140-6736(20)30566-3.; Guan WJ., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002032.; Luna G., Alping P., Burman J., Fink K., Fogdell-Hahn A., Gunnarsson M. et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020;77(2):184-191. https://doi.org/10.1001/]amaneurol.2019.3365.; Karamyan A., Dunser M.W., Wiebe DJ., Pilz G., Wipfler P, Chroust V. et al. Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study. PLoS One. 2016;11(5):e0155795. https://doi.org/10.1371/journal.pone.0155795.; Thompson AJ., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G. et al. Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. Lancet Neurol. 2018;17(2):162-173. https://doi.org/10.1016/S1474-4422(17)30470-2.; Авдеев С.Н., Адамян Л.В., Алексеева Е.И., Багненко С.Ф., Баранов А.А., Баранова Н.Н. и др. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 9 (26.10.2020). М.: Министерство здравоохранения Российской Федерации; 2020. 236 с. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf.; McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P, Lublin F.D. et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50(1):121-127. https://doi.org/10.1002/ana.1032.; Giovannoni G., Hawkes C., Lechner-Scott J., Levy M., Waubant E., Gold J. The COVID-19 Pandemic and the Use of MS Disease-Modifying Therapies. Mult Scler Relat Disord. 2020;39:102073. https://doi.org/10.1016/j.msard.2020.102073.; Barzegar M., Mirmosayyeb O., Nehzat N., Sarrafi R., Khorvash F., Maghzi A.H., Shaygannejad V. COVID-19 Infection in a Patient with Multiple Sclerosis Treated with Fingolimod. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e753. https://doi.org/10.1212/NXI.0000000000000753.; Berger J.R., Brandstadter R., Bar-Or A. COVID-19 and MS Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e761. https://doi.org/10.1212/NXI.0000000000000761.; Al-Ani M., Elemam N.M., Hundt J.E., Maghazachi AA. Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection? Infect Drug Resist. 2020;13:3243-3254. https://doi.org/10.2147/IDR.S269797.; Wolinsky J.S., Arnold D.L., Brochet B., Hartung H.P, Montalban X., Naismith R.T. et al. Long-Term Follow-Up from the ORATORIO Trial of Ocrelizumab for Primary Progressive Multiple Sclerosis: A Post-Hoc Analysis from the Ongoing Open-Label Extension of the Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Neurol. 2020;19(12):998-1009. https://doi.org/10.1016/S1474-4422(20)30342-2.; Louapre C., Collongues N., Stankoff B., Giannesini C., Papeix C., Bensa C. et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020;77(9):1079-1088. https://doi.org/10.1001/jamaneurol.2020.2581.; Montero-Escribano P, Matias-Guiu J., Gomez-Iglesias P, Porta-Etessam J., Pytel V., Matias-Guiu JA. Anti-CD20 and COVID-19 in Multiple Sclerosis and Related Disorders: A Case Series of 60 Patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185. https://doi.org/10.1016/j.msard.2020.102185.; Chaudhry F., Bulka H., Rathnam A.S., Said O.M., Lin J., Lorigan H. et al. COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection. J Neurol Sci. 2020;418:117147. https://doi.org/10.1016/j.jns.2020.117147.; Kuijpers T.W., Bende R.J., Baars P.A., Grummels A., Derks I.A., Dolman K.M. et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120(1):214-222. https://doi.org/10.1172/JCI40231.; Peeters L.M., Parciak T., Walton C., Geys L., Moreau Y., De Brouwer E. et al. COVID-19 in People with Multiple Sclerosis: A Global Data Sharing Initiative. Mult Scler. 2020;26(10):1157-1162. https://doi.org/10.1177/1352458520941485.
-
5Academic Journal
Authors: D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, E. M. Olyushina, K. I. Polyakova, A. G. Fisun, M. G. Grinin, K. A. Kokushkin
Source: Качественная клиническая практика, Vol 0, Iss 2, Pp 29-41 (2018)
Subject Terms: окрелизумаб, эффективность, безопасность, систематический обзор, первично-прогрессирующий рассеянный склероз, анти-в-клеточная терапия, моноклональные антитела, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441
File Description: electronic resource
-
6Academic Journal
Authors: O. V. Boyko, S. V. Petrov, N. Yu. Lashch, M. R. Guseva, A. N. Boyko, О. В. Бойко, С. В. Петров, Н. Ю. Лащ, М. Р. Гусева, А. Н. Бойко
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 1 (2019); 59-65 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 1 (2019); 59-65 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-1
Subject Terms: окрелизумаб, anti-B-cell therapy, pathogenetic treatment, ocrelizumab, анти-В-клеточная терапия, патогенетическое лечение
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1047/844; https://nnp.ima-press.net/nnp/article/view/1047/858; Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-74. doi:10.1159/000082102; Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan-Feb;5(1):22- 33. doi:10.4161/mabs.22771. Epub 2012 Dec 4.; Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun Rev. 2016 Jul;15(7):714-8. doi:10.1016/j.autrev.2016.03.006. Epub 2016 Mar 9.; Bittner S, Ruck T, Wiendl H, et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi:10.1177/1756285616666741. Epub 2016 Sep 2.; Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015 Jul 7;85(1):18-28. doi:10.1212/WNL.0000000000001587. Epub 2015 Apr 17.; Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007 Apr;130(Pt 4):1089-104.; Boiko OV, Khoroshilova II, Petrov SV, et al. Possible additional mechanisms of action of ocrelizumab in multiple sclerosis (on the example of a clinical case). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;(2):116-20. (In Russ.).; Gingele S, Jacobus TL, Konen FF, et al. Ocrelizumab depletes CD20? T cells in multiple sclerosis patients. Cells. 2018 Dec 28;8(1). pii: E12. doi:10.3390/cells8010012.; Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72 Suppl 1: 1-5. doi:10.1159/000367614. Epub 2014 Sep 26.; Hauser SL, Bar-Or A, Comi G, et al; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017 Jan 19; 376(3):221-234. doi:10.1056/NEJMoa1601277. Epub 2016 Dec 21.; Montalban X, Hauser SL, Kappos L, et al; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3): 209-220. doi:10.1056/NEJMoa1606468. Epub 2016 Dec 21.; Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018 Feb;24(2):96-120. doi:10.1177/1352458517751049. Epub 2018 Jan 20.; Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb; 17(2):162-173. doi:10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.; Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11): 1444-52.; Kremenchutzky M, Rice GP, Baskerville J, et al.The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006 Mar;129(Pt 3):584-94. Epub 2006 Jan 9.; Popova EV, Bryukhov VV, Boiko AN, Krotenkova MV. Primary-progressive multiple sclerosis as atypical demyelinating process. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;(2):42-6. (In Russ.).; Vlasov YaV, Churakov MV, Kurapov MA, et al. Primary-progressive multiple sclerosis in Russia: medical and sociological research involving patients and neurologists. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018; (2):40-6. (In Russ.).; Soerensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014 Jun;27(3):246-59. doi:10.1097/WCO.0000000000000096.; Boiko AN, Gusev EI. Modern algorithms of diagnosis and treatment of multiple sclerosis based on individual assessment of the patient's condition. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017; (2):92-106. (In Russ.).; Criteria of treatment failure and the cancellation of PITRS of the first line and replace to second-line drugs. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;(8-2):44. (In Russ.).; Инструкция по медицинскому применению окрелизумаба (OCREVUS®). Министерство здравоохранения Российской Федерации. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1e285065-d8dd-4438-b4f8-6358eced347c&t=c1311926-a0fe-4493-ba2b-e2874b4190f7.; Fox EJ, Markowitz C, Applebee A, et al. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Mult Scler. 2018 Dec;24(14):1862-1870. doi:10.1177/1352458518808189. Epub 2018 Nov 12.; Wolinsky J, Montalban X, Arnold DL, et al. Evaluation of No Evidence of Progression (NEP) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2017; February 23-25; Orlando, FL, USA. Poster P015.; Hauser SL, Belachew S, Kappos L. Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med. 2017 Apr 27;376(17):1694. doi:10.1056/NEJMc1702076.
-
7Academic Journal
Subject Terms: multiple sclerosis, 3. Good health, рассеянный склероз, окрелизумаб, progressive multiple sclerosis, изменяющие течение рас- сеянного склероза, первично-прогрессирующее течение, иммуномодулирующая терапия, препараты, ocrelizumab, моноклональные антитела, immunomodulatory therapy, monoclonal antibodies, disease-modifying therapies, В-лимфоциты, В-cell